🚀 AI is reshaping the future of healthcare diagnostics. According to MarketGenics, the global AI in Diagnostics Market is projected to grow from USD 2.6 Billion in 2025 to USD 14.3 Billion by 2035, r...

Volume 11, Issue 5 | January 30, 2025

Bracco Diagnostics Inc., a leader in diagnostic imaging solutions, and Subtle Medical, an innovator in artificial intelligence (AI) for medical imaging, have achieved a major milestone with the FDA clearance of AiMIFY™ software. This cutting-edge AI solution is designed to enhance magnetic resonance imaging (MRI) by streamlining imaging workflows, improving diagnostic efficiency, and providing advanced image analysis. What is AiMIFY™? AiMIFY™ is an AI-powered software that integrates seamlessly with MRI systems to enhance image quality, accelerate imaging processes, and optimize radiologists’ ability to detect abnormalities. Developed through a partnership between Bracco Diagnostics and Subtle Medical, AiMIFY™ aims to address common challenges in MRI diagnostics, such as:

Sonora Quest Laboratories told the Arizona Artificial Intelligence and Innovation Committee it has used AI for about a decade in lab workflows, described safeguards including human review and an FDA‑cleared cytology platform, and said its cyber audits and governance protect patient data.